Precigen, Inc.

NasdaqGS:PGEN Stock Report

Market Cap: US$345.6m

Precigen Management

Management criteria checks 2/4

Precigen's CEO is Helen Sabzevari, appointed in Jan 2020, has a tenure of 4.58 years. total yearly compensation is $3.72M, comprised of 26.9% salary and 73.1% bonuses, including company stock and options. directly owns 0.76% of the company’s shares, worth $2.62M. The average tenure of the management team and the board of directors is 5 years and 10.8 years respectively.

Key information

Helen Sabzevari

Chief executive officer

US$3.7m

Total compensation

CEO salary percentage26.9%
CEO tenure5yrs
CEO ownership0.8%
Management average tenure5yrs
Board average tenure10.8yrs

Recent management updates

Recent updates

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Feb 28
We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Precigen: RRP Targeting With AdenoVerse Technology Platform

Jan 20

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Nov 04
Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Jul 18
Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

May 15
Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Apr 18
Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Nov 10
Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen names Rutul Shah as chief operating officer

Sep 21

Circling Back On Precigen

Aug 23

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Aug 10
Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Precigen Q2 2022 Earnings Preview

Aug 07

Precigen to sell Trans Ova Genetics for $170M upfront

Jul 05

CEO Compensation Analysis

How has Helen Sabzevari's remuneration changed compared to Precigen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$140m

Jun 30 2024n/an/a

-US$135m

Mar 31 2024n/an/a

-US$97m

Dec 31 2023US$4mUS$1m

-US$96m

Sep 30 2023n/an/a

-US$85m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$79m

Dec 31 2022US$3mUS$1m

-US$80m

Sep 30 2022n/an/a

-US$84m

Jun 30 2022n/an/a

-US$103m

Mar 31 2022n/an/a

-US$108m

Dec 31 2021US$3mUS$1m

-US$111m

Sep 30 2021n/an/a

-US$124m

Jun 30 2021n/an/a

-US$125m

Mar 31 2021n/an/a

-US$110m

Dec 31 2020US$20mUS$1m

-US$104m

Sep 30 2020n/an/a

-US$100m

Jun 30 2020n/an/a

-US$122m

Mar 31 2020n/an/a

-US$138m

Dec 31 2019US$1mUS$500k

-US$169m

Sep 30 2019n/an/a

-US$373m

Jun 30 2019n/an/a

-US$381m

Mar 31 2019n/an/a

-US$414m

Dec 31 2018US$3mUS$500k

-US$375m

Compensation vs Market: Helen's total compensation ($USD3.72M) is above average for companies of similar size in the US market ($USD2.24M).

Compensation vs Earnings: Helen's compensation has increased whilst the company is unprofitable.

CEO

Helen Sabzevari (62 yo)

5yrs

Tenure

US$3,719,061

Compensation

Dr. Helen Sabzevari, Ph.D. MPH, served as Independent Director at Kinnate Biopharma Inc. from June 2021 to April 3, 2024. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intre...

Leadership Team

NamePositionTenureCompensationOwnership
Randal Kirk
Executive Chairman16.9yrsUS$600.00k0.39%
$ 1.4m
Helen Sabzevari
President5yrsUS$3.72m0.76%
$ 2.6m
Harry Thomasian
Chief Financial Officer3.3yrsUS$1.13m0.078%
$ 270.7k
Rutul Shah
Chief Operating Officerno dataUS$1.04m0.072%
$ 247.5k
Donald Lehr
Chief Legal Officer & Corporate Secretary14yrsUS$1.06m0.18%
$ 635.0k
Steven Harasym
VP & Head of Investor Relations7yrsno datano data
Rob Russell
VP & Head of Human Resourcesno datano datano data
Douglas Brough
Senior VP & Head of Researchno datano datano data
Bryan Butman
Senior VP & Head of CMCno datano datano data
Amy Lankford
Senior VP & Head of Clinical Operations and Regulatory Affairs1.6yrsno datano data
Phil Tennant
Chief Commercial Officerless than a yearno datano data
David Witte
Chief Executive Officer of MBP Titan LLC6yrsno datano data

5.0yrs

Average Tenure

62yo

Average Age

Experienced Management: PGEN's management team is seasoned and experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Randal Kirk
Executive Chairman16.9yrsUS$600.00k0.39%
$ 1.4m
Helen Sabzevari
President4.6yrsUS$3.72m0.76%
$ 2.6m
Jeffrey Kindler
Independent Director13.2yrsUS$319.00k0.13%
$ 464.2k
Fred Hassan
Independent Director8.6yrsUS$306.50k0.35%
$ 1.2m
Cesar Alvarez
Independent Director16.9yrsUS$312.50k0.19%
$ 672.5k
James Turley
Lead Independent Director10.8yrsUS$312.50k0.16%
$ 557.5k
Steven Frank
Independent Director16.9yrsUS$300.00k0.35%
$ 1.2m
Nancy Agee
Independent Directorless than a yearno data0.0060%
$ 20.8k
Vinita Gupta
Independent Director7.8yrsUS$306.50k0.16%
$ 537.6k

10.8yrs

Average Tenure

69yo

Average Age

Experienced Board: PGEN's board of directors are seasoned and experienced ( 10.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 09:07
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Precigen, Inc. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ying HuangBarclays
Derik de BruinBofA Global Research
Justin WalshB. Riley Securities, Inc.